The Ministry of Health has published EBOLA DRC - Evolution of the response to the Ebola outbreak in the provinces of North Kivu and Ituri on Thursday 31 January 2019. Excerpt from the Google translation:
EPIDEMIOLOGICAL SITUATION IN THE PROVINCES OF NORTH KIVU AND ITURI
Thursday 31 January 2019
The epidemiological situation of the Ebola Virus Disease dated January 30, 2019:
• Since the beginning of the epidemic, the cumulative number of cases is 759, 705 confirmed and 54 probable. In total, there were 468 deaths (414 confirmed and 54 probable) and 259 people cured.
• 178 suspected cases under investigation.
• 7 new confirmed cases, including 6 in Katwa and 1 in Butembo.
• 3 new deaths of confirmed cases, including
º 1 community death in Katwa
º 2 deaths at CTE, including 1 in Butembo and 1 in Katwa
/! \ The data presented in this table is subject to further changes after thorough investigation and after redistribution of cases and deaths in their health areas.
News of the response
Supported
• The Ebola Treatment Center (ETC) of Kayina, consisting of 8 beds, opened this Wednesday, January 30, 2019. This is the 10th CTE built after those of Beni, Bunia, Butembo, Goma, Katwa, Komanda Mandima Mangina and Tchomia.
Vaccination
• More than 70,000 people were vaccinated in 28 health zones, spread among four provinces of the Democratic Republic of Congo. Since the beginning of vaccination on 8 August 2018, 70,611 people have been vaccinated , including 20,321 in Beni, 16,657 in Katwa, 7,939 in Butembo, 6,008 in Mabalako, 2,656 in Kalunguta, 2,110 in Komanda, 1,911 in Goma, 1,821 in Oicha, 1,663 in Mandima, 1,157 in Karisimbi, 883 in Kayina, 877 in Vuhovi, 842 in Kyondo, 750 in Masereka, 700 in Lubero, 599 in Mutwanga, 590 in Rutshuru, 554 in Bunia, 527 in Nyankunde, 524 in Biena, 442 in Musienene, 355 in Tchomia, 179 in Mangurujipa, 167 in Kirotshe, 154 in Alimbongo, 125 in Nyiragongo, 87 in Watsa (Haut-Uélé) and 13 in Kisangani.
• The only vaccine to be used in this outbreak is the rVSV-ZEBOV vaccine, manufactured by the pharmaceutical group Merck, following approval by the Ethics Committee in its decision of 19 May 2018.
